Environmental contamination across multiple hospital departments with multidrug-resistant bacteria pose an elevated risk of healthcare-associated infections in Kenyan hospitals.
Antibiotic resistance
Healthcare-associated infections
Hospital environment
Multi-drug resistance
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
29 03 2023
29 03 2023
Historique:
received:
10
06
2022
accepted:
06
03
2023
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Healthcare-associated infections (HAIs) are often caused by multidrug-resistant (MDR) bacteria contaminating hospital environments which can cause outbreaks as well as sporadic transmission. This study systematically sampled and utilized standard bacteriological culture methods to determine the numbers and types of MDR Enterococcus faecalis/faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli (ESKAPEE) from high-touch environments of five Kenyan hospitals; level 6 and 5 hospitals (A, B, and C), and level 4 hospitals (D and E), in 2018. Six hundred and seventeen high-touch surfaces across six hospital departments; surgical, general, maternity, newborn, outpatient and pediatric were sampled. 78/617 (12.6%) of the sampled high-touch surfaces were contaminated with MDR ESKAPEE; A. baumannii, 23/617 (3.7%), K. pneumoniae, 22/617 (3.6%), Enterobacter species, 19/617 (3.1%), methicillin resistant S. aureus (MRSA), 5/617 (0.8%), E. coli, 5/617 (0.8%), P. aeruginosa, 2/617 (0.3%), and E. faecalis and faecium, 2/617 (0.3%). Items found in patient areas, such as beddings, newborn incubators, baby cots, and sinks were the most frequently contaminated. Level 6 and 5 hospitals, B, 21/122 (17.2%), A, 21/122 (17.2%), and C, 18/136 (13.2%), were more frequently contaminated with MDR ESKAPEE than level 4 hospitals; D, 6/101 (5.9%), and E, 8/131 (6.1%). All the sampled hospital departments were contaminated with MDR ESKAPEE, with high levels observed in newborn, surgical and maternity. All the A. baumannii, Enterobacter species, and K. pneumoniae isolates were non-susceptible to piperacillin, ceftriaxone and cefepime. 22/23 (95.6%) of the A. baumannii isolates were non-susceptible to meropenem. In addition, 5 K. pneumoniae isolates were resistant to all the antibiotics tested except for colistin. The presence of MDR ESKAPEE across all the hospitals demonstrated gaps in infection prevention practices (IPCs) that should be addressed. Non-susceptibility to last-line antibiotics such as meropenem threatens the ability to treat infections.
Sections du résumé
BACKGROUND
Healthcare-associated infections (HAIs) are often caused by multidrug-resistant (MDR) bacteria contaminating hospital environments which can cause outbreaks as well as sporadic transmission.
METHODS
This study systematically sampled and utilized standard bacteriological culture methods to determine the numbers and types of MDR Enterococcus faecalis/faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli (ESKAPEE) from high-touch environments of five Kenyan hospitals; level 6 and 5 hospitals (A, B, and C), and level 4 hospitals (D and E), in 2018. Six hundred and seventeen high-touch surfaces across six hospital departments; surgical, general, maternity, newborn, outpatient and pediatric were sampled.
RESULTS
78/617 (12.6%) of the sampled high-touch surfaces were contaminated with MDR ESKAPEE; A. baumannii, 23/617 (3.7%), K. pneumoniae, 22/617 (3.6%), Enterobacter species, 19/617 (3.1%), methicillin resistant S. aureus (MRSA), 5/617 (0.8%), E. coli, 5/617 (0.8%), P. aeruginosa, 2/617 (0.3%), and E. faecalis and faecium, 2/617 (0.3%). Items found in patient areas, such as beddings, newborn incubators, baby cots, and sinks were the most frequently contaminated. Level 6 and 5 hospitals, B, 21/122 (17.2%), A, 21/122 (17.2%), and C, 18/136 (13.2%), were more frequently contaminated with MDR ESKAPEE than level 4 hospitals; D, 6/101 (5.9%), and E, 8/131 (6.1%). All the sampled hospital departments were contaminated with MDR ESKAPEE, with high levels observed in newborn, surgical and maternity. All the A. baumannii, Enterobacter species, and K. pneumoniae isolates were non-susceptible to piperacillin, ceftriaxone and cefepime. 22/23 (95.6%) of the A. baumannii isolates were non-susceptible to meropenem. In addition, 5 K. pneumoniae isolates were resistant to all the antibiotics tested except for colistin.
CONCLUSION
The presence of MDR ESKAPEE across all the hospitals demonstrated gaps in infection prevention practices (IPCs) that should be addressed. Non-susceptibility to last-line antibiotics such as meropenem threatens the ability to treat infections.
Identifiants
pubmed: 36978195
doi: 10.1186/s13756-023-01227-x
pii: 10.1186/s13756-023-01227-x
pmc: PMC10053033
doi:
Substances chimiques
Meropenem
FV9J3JU8B1
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Informations de copyright
© 2023. The Author(s).
Références
MMWR Recomm Rep. 2003 Jun 6;52(RR-10):1-42
pubmed: 12836624
Appl Environ Microbiol. 2001 Jul;67(7):3325-7
pubmed: 11425763
BMC Microbiol. 2014 May 08;14:118
pubmed: 24885173
J Hosp Infect. 2012 Jan;80(1):56-60
pubmed: 21975219
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32938614
J Res Pharm Pract. 2019 Oct 16;8(3):149-154
pubmed: 31728346
Antimicrob Agents Chemother. 2003 Apr;47(4):1251-6
pubmed: 12654654
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents
pubmed: 19136439
BMC Pediatr. 2014 Apr 17;14:105
pubmed: 24742105
Infect Control Hosp Epidemiol. 2010 Aug;31(8):850-3
pubmed: 20569115
Afr J Infect Dis. 2016 May 01;10(2):89-95
pubmed: 28480442
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
pubmed: 16355321
Int J Environ Res Public Health. 2021 Jun 25;18(13):
pubmed: 34201911
Future Microbiol. 2012 Jul;7(7):887-902
pubmed: 22827309
Clin Microbiol Rev. 2008 Jul;21(3):538-82
pubmed: 18625687
Can J Infect Dis Med Microbiol. 2018 Apr 29;2018:1525072
pubmed: 29854033
Antimicrob Agents Chemother. 2010 Jan;54(1):109-15
pubmed: 19841152
Int J Environ Res Public Health. 2018 Oct 19;15(10):
pubmed: 30347749
Int J Infect Dis. 2013 Dec;17(12):e1255-8
pubmed: 24176550
PLoS One. 2018 Aug 22;13(8):e0201961
pubmed: 30133491
Antimicrob Agents Chemother. 2002 Jan;46(1):1-11
pubmed: 11751104
J Clin Microbiol. 1998 Jul;36(7):1938-41
pubmed: 9650940
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Commun Med (Lond). 2022 Jun 1;2:62
pubmed: 35664456
PLoS One. 2013 Nov 11;8(11):e78942
pubmed: 24244390
Nat Rev Microbiol. 2004 Feb;2(2):95-108
pubmed: 15040259
Access Microbiol. 2020 Sep 18;2(12):acmi000171
pubmed: 33490867
Am J Infect Control. 2013 May;41(5 Suppl):S6-11
pubmed: 23622751
PLoS One. 2021 Feb 22;16(2):e0246937
pubmed: 33617559
South Med J. 2011 Jan;104(1):40-5
pubmed: 21119555
Infect Dis Ther. 2017 Jun;6(2):199-211
pubmed: 28357705
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207
Lancet. 2011 Dec 10;378(9808):2021-2027
pubmed: 22133536
Curr Infect Dis Rep. 2018 Apr 27;20(6):12
pubmed: 29704133
Int J Infect Dis. 2021 Feb;103:469-477
pubmed: 33333248
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
J Glob Antimicrob Resist. 2014 Sep;2(3):190-193
pubmed: 27873728
J Hosp Infect. 2008 May;69(1):8-23
pubmed: 18355943
East Afr Med J. 2005 Jul;82(7):357-61
pubmed: 16167709
J Hosp Infect. 1999 Jun;42(2):113-7
pubmed: 10389060
Infect Control. 1985 Feb;6(2):68-74
pubmed: 3882593
Afr J Lab Med. 2018 Dec 06;7(2):796
pubmed: 30568902
Virulence. 2012 May 1;3(3):243-50
pubmed: 22546906
Front Pediatr. 2019 Mar 29;7:101
pubmed: 30984722
Genes Dis. 2019 Apr 17;6(2):109-119
pubmed: 31194018
Antimicrob Agents Chemother. 2015 Jan;59(1):714-6
pubmed: 25348541
An Pediatr (Engl Ed). 2019 Jul;91(1):13-20
pubmed: 31280816